Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 111   

Articles published

LGND 88.94 -3.48 (-3.77%)
price chart
Insider Deal: David Knott Unloaded 200 Shares of Ligand Pharmaceuticals Inc ...
The Ligand Pharmaceuticals Inc. (NASDAQ:LGND) 86.79 +0.73 0.84% 's director, David Knott, an insider sold - 200 Ligand Pharmaceuticals Inc's shares, based on the average stock price of $99.0 per each share. The unloaded shares had a value of approx.
Ligand Pharmaceuticals Inc (LGND) Files Form 4 Insider Selling : David M ...  Insider Trading Report
A Director at Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is Selling Shares  Markets.co
Ligand Pharmaceuticals Inc (NASDAQ:LGND) Q2 Financial Report
Ligand Pharmaceuticals Inc (NASDAQ:LGND) stock is currently trading 0.58% below its 52-week-high, 160.32% above its 52-week-low.
Ligand Pharmaceuticals Inc.: Ligand Reports Second Quarter 2015 Financial ...  The Wall Street Transcript
Ligand Pharmaceuticals Beats on Q2 Earnings, Affirms View  Zacks.com
Company Update (NASDAQ:LGND): Ligand Pharmaceuticals Inc. Receives CHMP ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Revolade´┐Ż (eltrombopag), a Novartis product, for the treatment ...
Ligand Pharma: Revolade Recommended By CHMP For EU Approval To Treat SAA  Nasdaq
Ligand Pharmaceuticals Inc. (LGND) Enters into Commercial License and Supply ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces it has entered into a global license and supply agreement with Sanofi SA (ADR) (NYSE:SNY) to utilize Captisol in the development and commercialization of SAR-125844, a potent MET kinase ...
Ligand Pharmaceuticals Inc.: Ligand Enters into Commercial License and ...  The Wall Street Transcript
Ligand Enters into Commercial License and Supply Agreement with Sanofi for ...  MarketWatch
Ligand Pharmaceuticals Inc (LGND) Disclose Form-4 Insider Selling of David M ...
Ligand Pharmaceuticals Inc (LGND): David M Knott , director of Ligand Pharmaceuticals Inc sold 4,000 shares on Aug 17, 2015.
Large Outflow of Money Witnessed in Ligand Pharmaceuticals Incorporated  Money Flow Index
Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Drops by -9.85%  OTC Outlook
Ligand Pharmaceuticals Inc Blair William & CoIl Bought New Stake
Blair William & CoIl has filled a SC 13G/A form regarding Ligand Pharmaceuticals Inc 91.94 0.00 % . Filing Link: 000114420415040828.
Company Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Rally 12.34%
Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) appreciated by 12.34% during the past week but lost 12.21% on a 4-week basis.
Wall Street Puts $120 Price Target on Ligand Pharmaceuticals Incorporated ...  Markets Daily
Morning Buzz: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Sirius XM ...  Stock Transcript
Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Stock a Sell after Jason Aryeh's ...
The insider Jason Aryeh who is director of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) 89.78 -2.16 -2.35% sold 9,240 shares of the public firm having a market value of $807,047 USD at an average $87.3 per share.
Ligand Pharmaceuticals Inc (LGND) Insider Selling : Jason Aryeh Sells 9240 ...  Money Flow Index
Ligand Pharmaceuticals Inc (LGND) Files Form 4 Insider Selling : David M Knott ...
Ligand Pharmaceuticals Inc (LGND): David M Knott , director of Ligand Pharmaceuticals Inc sold 4,000 shares on Aug 17, 2015.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Brokerage Rating Update  Investor Newswire
Matthew Foehr Unloaded 23046 Shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND)
The President and COO of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) 86.06 +2.88 3.46% and firm's insider Matthew Foehr made a sale of 23,046 shares of the firm based on the price of stock which is $96.5 per each share.
Ligand Pharmaceuticals Inc (LGND) Files Form 4 Insider Selling : Matthew W ...  Insider Trading Report
Why Ligand Pharmaceuticals (LGND) Could Be Positioned for a Surge?  Zacks.com